| 摘要 |
The invention concerns a product comprising at least mikanolide, dihydromikanolide or an analogue thereof combined with at least another anti-cancer agent for simultaneous, separate or prolonged therapeutic use in cancer treatment. In a preferred embodiment of the invention, the mikanolide, dihydromikanolide or one analogue thereof is combined with enzymatic inhibitors such as G heterotrimeric protein inhibitors or alkylating agents such as cis-platinum.
|
